Key Takeaways
- • The UK's Advanced Research and Invention Agency (Aria) has allocated £50 million—more than 12.5% of its £400 million R&D budget over two years—to 14 US tech companies and venture capital firms, raising scrutiny over public fund deployment.
- • Rain Neuromorphics, an Aria-funded company backed by OpenAI CEO Sam Altman, was reported near collapse following its grant award, with two founders appearing to have departed, yet continues delivering projects for the agency with unclear returns for the UK.
- • Aria, created by Dominic Cummings to fund "moonshot" scientific projects and restore Britain's position as a scientific superpower, faces criticism from academics and lawmakers for effectively subsidizing US tech ecosystem expansion rather than driving domestic economic benefit.
- • Chi Onwurah, chair of the Commons science and technology committee, has called for stronger scrutiny of Aria's spending practices, noting the agency's statutory obligation to drive UK economic growth, scientific innovation, and quality of life improvements.
Summary
Britain's Advanced Research and Invention Agency, a government body established by former aide Dominic Cummings to fund high-risk scientific ventures, has directed over £50 million in taxpayer funding to US technology companies and venture capital groups. According to a joint investigation by The Guardian and Democracy for Sale, this allocation represents more than one-eighth of Aria's £400 million research and development budget deployed over the past two years, raising questions about the agency's mandate to benefit the UK economy.
The case of Rain Neuromorphics exemplifies the concerns. The company, which received Aria funding and counts OpenAI CEO Sam Altman as a backer, was reported to be approaching financial collapse shortly after securing its grant. Two of its founders have apparently departed the organization, yet the company continues to deliver projects under its Aria contract with no publicly articulated return on investment for UK taxpayers or clear domestic benefit.
Cecilia Rikap, an economics professor at University College London, characterized the spending pattern as a misrepresentation of Aria's stated purpose. She argued that under the guise of supporting moonshot projects, the agency is effectively channeling public resources to strengthen the dominance of the US technology sector, a concern she attributed to broader government alignment with American tech interests.
Chi Onwurah, chair of the House of Commons science and technology committee, has signaled demand for enhanced oversight of Aria's allocation decisions. She emphasized that the Aria Act explicitly requires the organization to generate measurable benefits for the UK through economic growth, scientific innovation advancement, and quality-of-life improvements—benchmarks that appear inconsistent with the current geographic distribution of grants. The committee chair noted that this accountability requirement was discussed when Aria's leadership appeared before the committee in 2025.
The case of Rain Neuromorphics exemplifies the concerns. The company, which received Aria funding and counts OpenAI CEO Sam Altman as a backer, was reported to be approaching financial collapse shortly after securing its grant. Two of its founders have apparently departed the organization, yet the company continues to deliver projects under its Aria contract with no publicly articulated return on investment for UK taxpayers or clear domestic benefit.
Cecilia Rikap, an economics professor at University College London, characterized the spending pattern as a misrepresentation of Aria's stated purpose. She argued that under the guise of supporting moonshot projects, the agency is effectively channeling public resources to strengthen the dominance of the US technology sector, a concern she attributed to broader government alignment with American tech interests.
Chi Onwurah, chair of the House of Commons science and technology committee, has signaled demand for enhanced oversight of Aria's allocation decisions. She emphasized that the Aria Act explicitly requires the organization to generate measurable benefits for the UK through economic growth, scientific innovation advancement, and quality-of-life improvements—benchmarks that appear inconsistent with the current geographic distribution of grants. The committee chair noted that this accountability requirement was discussed when Aria's leadership appeared before the committee in 2025.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.